Medicine and Dentistry
Child
100%
Prophylaxis
100%
Palivizumab
100%
Persistent Truncus Arteriosus
66%
Infection
50%
Surgery
50%
Human Respiratory Syncytial Virus
50%
Patient
33%
Lesion
33%
Injection
33%
Therapeutic Procedure
16%
Diseases
16%
Association
16%
Age
16%
Heart Disease
16%
Cardiopulmonary Bypass
16%
Intramuscular Injection
16%
Pulmonary Hypertension
16%
Cardiomyopathy
16%
Lung Blood Flow
16%
Nursing and Health Professions
Prophylaxis
100%
Infant
100%
Palivizumab
100%
Congenital Heart Disease
66%
Infection
50%
Surgery
50%
Physician
33%
Injection
33%
Clinician
16%
Dose
16%
Diseases
16%
Complication
16%
Hospital Admission
16%
Cardiopulmonary Bypass
16%
Pediatrics
16%
Intramuscular Drug Administration
16%
Pulmonary Hypertension
16%
Heart Disease
16%
Cardiomyopathy
16%
Lung Blood Flow
16%
Pharmacology, Toxicology and Pharmaceutical Science
Palivizumab
100%
Congenital Heart Disease
66%
Infection
50%
Human Respiratory Syncytial Virus
50%
Diseases
16%
Complication
16%
Heart Disease
16%
Virus
16%
Cardiomyopathy
16%
Intramuscular Injection
16%
Pulmonary Hypertension
16%
Cyanosis
16%
Biochemistry, Genetics and Molecular Biology
Palivizumab
100%
Human Respiratory Syncytial Virus
50%
Dose
16%
Association
16%
Age
16%
Pediatrics
16%
Virus
16%
Lung Blood Flow
16%
Immunology and Microbiology
Palivizumab
100%
Human Respiratory Syncytial Virus
50%
Dose
16%
Age
16%
Association
16%
Lung Blood Flow
16%